Aclaris Therapeutics (NASDAQ:ACRS) Earns “Buy” Rating from HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 366.47% from the stock’s current price.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $3.43 on Wednesday. The stock has a market capitalization of $371.64 million, a PE ratio of -2.49 and a beta of 0.41. The business’s 50 day simple moving average is $3.09 and its 200 day simple moving average is $2.34. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $3.30 million during the quarter, compared to the consensus estimate of $1.59 million. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. As a group, research analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC purchased a new stake in Aclaris Therapeutics in the 2nd quarter worth approximately $26,000. AXQ Capital LP purchased a new stake in shares of Aclaris Therapeutics in the third quarter worth $27,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Aclaris Therapeutics during the second quarter valued at $28,000. XTX Topco Ltd purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at about $34,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Aclaris Therapeutics during the 2nd quarter valued at about $48,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.